Orcrist Bio Inc. (ORC) has announced the application to the Competent Authority of Seville (Spain) test security open-label Phase I of a single ascending dose in healthy men on HYC750 volunteers. The aim of this study is to evaluate the safety, tolerance, pharmacokinetics and pharmacodynamics (induction of hematopoiesis) of HYC750, a formulation patent protection hialuronano.
ORC used his experience and knowledge of rules Kinesis Pharma BV for sending the clinical trial. The trial is scheduled to perform through INPEC BV in its center clinical trial in Malaga (Spain).
The doctorThomas ICHIM, chairman of the scientific advice of ORC, said, "HYC750 has a pharmacological profile and pharmacodynamic very favorable, and is an excellent candidate for clinical development a rapid and dynamic."